

## **CURRICULUM VITAE**

<b>Name</b>	James L Zehnder	<b>Country</b>	USA
<b>Current Position</b>	Professor of Pathology and Medicine (Hematology) Director of Clinical Pathology, Department of Pathology Stanford University School of Medicine		

<b>Educational Background</b>		
1984	M.D.	Tufts University School of Medicine
1979	B.A.	University of California, Santa Cruz (Chemistry)

<b>Professional Experience</b>	
2007.8.-present	Professor of Pathology, Stanford University School of Medicine
1999.3.-2007.7.	Associate Professor of Pathology, Stanford University School of Medicine
1994.3.-1999.2.	Assistant Professor of Pathology, Stanford University School of Medicine
1994.2.	Acting Assistant Professor of Pathology, Stanford University School of Medicine
1993.7.-1994.2.	Post-doctoral Fellow, Laboratory of Dr. Eugene Butcher, Department of Pathology, Stanford
1991.7.-1992.6.	NIH Oncology Training Grant
1991.7.-1993.6.	Post-doctoral Fellow, Laboratory of Dr. Lawrence Leung, Department of Medicine (Hematology), Stanford
1989.7.-1991.6.	American Heart Association, California Affiliate Post-doctoral Fellowship
1988.7.-1991.6.	Hematology and Oncology Fellowships, Stanford University Medical Center
1988.6.-1987.7.	Chief Resident in Medicine, Stanford University Medical Center
1987.6.-1985.7.	Residency in Medicine: Stanford University Medical Center
1984.7.-1985.6.	Internship in Medicine: Stanford University Medical Center

### Professional Organizations

American Society of Hematology  
 Hemostasis Scientific Committee, American Society of Hematology 2003-8  
 Association for Molecular Pathology  
 International Society for Laboratory Hematology, organizing committee for annual meeting, 2010-14; Program co-chair 2015, 2017 annual meetings  
 International Society for Thrombosis and Haemostasis, biannual meeting organizing committee, 2015 Toronto  
 Steering committee, Thrombosis and Hemostasis Summit of North America, 2012-present  
 Elected to President, North American Specialized Coagulation Laboratory Association 2014-16 (Previously Member at large 2005-7, Treasurer 2007-11, Vice President 2011-13)  
 Hematology Peer Reviewer, UpToDate 2005 – present  
 NIH LRP review committee 2011-2020  
 Canadian Institutes of Health Research Peer Review Member, Haematology, Digestive Disease & Kidney 2007-2021  
 University of Kuwait Faculty of Medicine, Peer Reviewer 2013, 2015  
 FDA Review Panel: Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) 2022- present

### Main Scientific Publications

1. Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations. Zhang H, Chien M, Hou Y, Shomali W, Brar RS, Ho C, Han P, Xu D, Zhang BM, Guo X, Tolentino LL, Wu NC, Tsai AG, Jin J, Witteles WH, Chen Z, Abidi P, Jangam D, Krieger MS, Craig M, Bussel JB, Gotlib JR, **Zehnder JL**. Blood Adv. 2023 Jan 10;7(1):190-194.
2. Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor. Tung JK, Jangam D, Ho CC, Fung E, Khodadoust MS, Kim YH, **Zehnder JL**, Stehr H, Zhang BM. J Mol Diagn. 2023 Mar 2:S1525-1578(23)00045-4.
3. The role of CD8+ T cell clones in immune thrombocytopenia. Malik A, Sayed AA, Han P, Tan MMH, Watt E, Constantinescu-Bercu A, Cocker ATH, Khoder A, Saputitl RC, Thorley EV, Teklemichael A, Ding Y, Hart ACJ, Zhang H, Mitchell WA, Imami N, Crawley JTB, Salles-Crawley II, Bussel JB, **Zehnder JL**, Adams SP, Zhang BM, Cooper N. Blood. 2023 Feb 7:blood.2022018380.

4. Balancing the Qi in ITP. **Zehnder JL**. Blood. 2022 Dec 29;140(26):2768-2770.
5. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias. Testa S, Kumar J, Goodell AJ, **Zehnder JL**, Alexander KM, Sidana S, Arai S, Witteles RM, Liedtke M. Semin Oncol. 2022 Dec 1:S0093-7754(22)00086-0.
6. Diagnostic Impact of Next-Generation Sequencing Panels for Lymphoproliferative Neoplasms on Small-Volume Biopsies. Fei F, Natkunam Y, **Zehnder JL**, Stehr H, Gratzinger D. Am J Clin Pathol. 2022 Sep 2;158(3):345-361.
7. Machine Learning Predictability of Clinical Next Generation Sequencing for Hematologic Malignancies to Guide High-Value Precision Medicine. Kim GYE, Noshad M, Stehr H, Rojansky R, Gratzinger D, Oak J, Brar R, Iberri D, Kong C, **Zehnder J**, Chen JH. AMIA Annu Symp Proc. 2022 Feb 21;2021:641-650. eCollection 2021.
8. DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples. Baker SA, Jin J, Pfaffroth C, Vu T, **Zehnder JL**. Res Pract Thromb Haemost. 2021 Jan 27;5(2):314-325.
9. Performance Characteristics of Mutational Signature Analysis in Targeted Panel Sequencing. Lawrence L, Kunder CA, Fung E, Stehr H, **Zehnder J**. Arch Pathol Lab Med. 2021 Nov 1;145(11):1424-1431.
10. Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports. Rojansky R, Fernandez-Pol S, Wang E, Rieger KE, Novoa RA, **Zehnder JL**, Kunder CA, Kim YH, Khodadoust MS, Brown RA. Diagn Pathol. 2020 Sep 28;15(1):122.
11. Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant. Zheng P, Tamaresis J, Thangavelu G, Xu L, You X, Blazar BR, Negrin RS, **Zehnder JL**, Iliopoulou BP, Meyer EH. Blood Adv. 2020 Sep 8;4(17):4232-4243.
12. Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. Zhang H, Zhang BM, Guo X, Xu L, You X, West RB, Bussel JB, **Zehnder JL**. Haematologica. 2020 Mar;105(3):e129-e132.

